<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03683914</url>
  </required_header>
  <id_info>
    <org_study_id>vaginal dinoprostone</org_study_id>
    <nct_id>NCT03683914</nct_id>
  </id_info>
  <brief_title>Vaginal Dinoprostone Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients</brief_title>
  <official_title>Vaginal Dinoprostone Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients: A Randomized Double-Blind Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effectiveness of vaginal dinoprostone with placebo in minimising the pain
      experienced by postmenopausal patients during diagnostic ofﬁce hysteroscopy and to assess the
      ease of insertion of hysteroscope as reported by the hysteroscopist.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      hysteroscopy is commonly used in the diagnosis and treatment of intrauterine lesions such as
      polyps, ﬁbroids, septa, and adhesions, and in the presence of abnormal bleeding and during
      the removal of an intrauterine device or foreign body.Cervical ripening is made possible by
      the use of medication through different routes.The most commonly used agent is misoprostol,a
      synthetic prostaglandin E1 (PGE1) analogue that is frequently administered in off-label use
      in obstetrics and gynaecology for medical abortion, labor induction, endometrial biopsy,
      dilatation and curettage, intrauterine device insertion, myomectomy, postpartum haemorrhage,
      and cervical ripening.In contrast, dinoprostone, a natural PGE2, is mostly used in obstetrics
      for cervical ripening and the stimulation of uterine contractions to induce labor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2018</start_date>
  <completion_date type="Actual">February 28, 2019</completion_date>
  <primary_completion_date type="Actual">January 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity of pain</measure>
    <time_frame>an expected average of 10 minutes</time_frame>
    <description>Pain intensity will be assessed by visual analogue scale during the procedure.visual analogue scale ranging from 0 to 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensity of pain</measure>
    <time_frame>30 minutes after the procedure</time_frame>
    <description>Pain intensity will be assessed by visual analogue scale 30 minutes after the procedure.visual analogue scale ranging from 0 to 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>an expected average 10 minutes</time_frame>
    <description>From the introduction of hysteroscope into the vagina till compilation of hysteroscopic examination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Office Hysteroscopy</condition>
  <arm_group>
    <arm_group_label>dinoprostone arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia &amp; Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinoprostone 3Mg Vaginal Tablet</intervention_name>
    <description>1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia &amp; Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.</description>
    <arm_group_label>dinoprostone arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo vaginal tablet</intervention_name>
    <description>1 vaginal tablet of placebo inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Menopausal patients with an indication for ofﬁce hysteroscopy (postmenopausal bleeding
             or abnormal ultrasound ﬁndings)

        Exclusion Criteria:

          -  • Nulliparous patients

               -  patients with cervical pathology

               -  retroverted uterus (detected by transvaginal ultrasound)

               -  previous cervical surgery

               -  patients with severe vaginal bleeding

               -  allergy or contraindications to dinoprostone therapy (asthma, liver, kidney, or
                  heart disease).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AHMED SAMY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>11231</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 22, 2018</study_first_submitted>
  <study_first_submitted_qc>September 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>March 22, 2019</last_update_submitted>
  <last_update_submitted_qc>March 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Samy aly ashour</investigator_full_name>
    <investigator_title>lecturer in obstetrics and gynecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

